• Company
• ILSUNG signs 3rd generation CCB HTN tx co-promotion
• by Lee, Seok-Jun Oct 6, 2022 06:05am

• Company
• Koselugo is keen to discuss the registration of benefits
• by Eo, Yun-Ho Oct 5, 2022 06:11am

• Opinion
• [Reporter’s View] Real crisis will come after COVID-19
• by Kim, Jin-Gu Oct 5, 2022 06:11am

• Company
• Moderna's Spikevax bivalent Original/Omicron BA.1
• by Oct 5, 2022 06:11am

• Policy
• Data for reevaluation to be submitted from the 24th
• by Lee, Tak-Sun Oct 5, 2022 06:11am

• Policy
• Pfizer Corona vaccine passed a verification advisory group
• by Lee, Hye-Kyung Oct 5, 2022 06:10am

• Policy
• Post-marketing surveillance of breast cancer drug Kadcyla
• by Lee, Hye-Kyung Oct 4, 2022 06:07am

• Opinion
• [Reporter's view] Reimbursement of Zerbaxa
• by Eo, Yun-Ho Oct 4, 2022 06:07am

• Company
• Il-Yang “has not exaggerated COVID-19 trial results
• by Kim, Jin-Gu Oct 4, 2022 06:07am

• Company
• Pharmaceuticals trying to dominate Saxenda obesity market
• by Moon, sung-ho Oct 4, 2022 06:07am